Total Payments
$124,878
2024 Payments
$20,017
Companies
20
Transactions
163
Medicare Patients
8,397
Medicare Billing
$4.4M
Payment Breakdown by Category
Consulting$61,634 (49.4%)
Travel$25,709 (20.6%)
Other$23,059 (18.5%)
Research$8,497 (6.8%)
Food & Beverage$5,979 (4.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,634 | 24 | 49.4% |
| Travel and Lodging | $25,709 | 47 | 20.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,059 | 8 | 18.5% |
| Unspecified | $8,497 | 5 | 6.8% |
| Food and Beverage | $5,979 | 79 | 4.8% |
Payments by Type
General
$116,381
158 transactions
Research
$8,497
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $25,453 | 35 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $24,326 | 13 | $0 (2024) |
| Incyte Corporation | $15,023 | 22 | $0 (2024) |
| EISAI INC. | $10,873 | 25 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $8,221 | 7 | $0 (2023) |
| Genentech USA, Inc. | $8,168 | 15 | $0 (2024) |
| Celgene Corporation | $7,770 | 2 | $0 (2018) |
| Astellas Pharma US Inc | $5,097 | 3 | $0 (2017) |
| Daiichi Sankyo Inc. | $4,375 | 2 | $0 (2021) |
| Ipsen Biopharmaceuticals, Inc | $4,276 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,017 | 24 | Bayer Healthcare Pharmaceuticals Inc. ($11,470) |
| 2023 | $5,636 | 11 | Exelixis Inc. ($4,489) |
| 2022 | $16,546 | 29 | Exelixis Inc. ($8,049) |
| 2021 | $9,481 | 8 | Daiichi Sankyo Inc. ($4,375) |
| 2020 | $16,945 | 13 | Exelixis Inc. ($5,721) |
| 2019 | $14,697 | 24 | EISAI INC. ($6,162) |
| 2018 | $14,033 | 12 | Celgene Corporation ($6,699) |
| 2017 | $27,521 | 42 | Bayer HealthCare Pharmaceuticals Inc. ($9,796) |
All Payment Transactions
163 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $6,850.00 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $507.95 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $66.00 | General |
| 11/22/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $39.45 | General |
| 11/22/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $26.99 | General |
| 11/22/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $17.49 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $291.96 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $151.09 | General |
| 11/21/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $137.17 | General |
| 11/21/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $17.49 | General |
| 09/24/2024 | Johnson & Johnson Surgical Vision, Inc. | Tecnis IOL (Device) | Food and Beverage | In-kind items and services | $49.78 | General |
| Category: Optics | ||||||
| 06/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $315.60 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $1,025.98 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $177.13 | General |
| Category: Oncology | ||||||
| 06/27/2024 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $82.27 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $7,353.20 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $355.28 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $315.65 | General |
| Category: Oncology | ||||||
| 06/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Travel and Lodging | In-kind items and services | $177.13 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $45.12 | General |
| Category: BioOncology | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/19/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: BioOncology | ||||||
| 12/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $237.19 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AX-CL-OTHER-PI-003908 - A phase II study of gemcitabine, cisplatin and Abraxane in advanced biliary cancers | Celgene Corporation | $6,699 | 1 |
| NCI-2015-00578 | Celgene Corporation | $1,071 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $588.00 | 1 |
| BAY94 9343 Solid Tumor Multi Cohort Trial | Bayer HealthCare Pharmaceuticals Inc. | $138.59 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 53 | 2,055 | 55,319 | $6.3M | $1.2M |
| 2022 | 52 | 2,365 | 56,344 | $6.4M | $1.3M |
| 2021 | 40 | 1,833 | 31,496 | $3.8M | $857,082 |
| 2020 | 52 | 2,144 | 43,683 | $5.5M | $1.1M |
Total Patients
8,397
Total Services
186,842
Medicare Billing
$4.4M
Procedure Codes
197
All Medicare Procedures & Services
197 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 52 | 11,160 | $2.2M | $418,945 | 18.8% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 33 | 7,404 | $1.6M | $318,296 | 19.9% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 13 | 6,880 | $826,248 | $162,017 | 19.6% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 20 | 1,130 | $156,460 | $40,615 | 26.0% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 20 | 1,630 | $327,395 | $38,474 | 11.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 1,980 | $178,548 | $35,559 | 19.9% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 17 | 1,245 | $238,318 | $31,031 | 13.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 212 | 248 | $181,536 | $24,678 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 165 | 256 | $85,760 | $23,414 | 27.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 27 | 109 | $40,984 | $14,472 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 65 | 65 | $47,775 | $10,671 | 22.3% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 132 | $124,423 | $10,376 | 8.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 72 | 95 | $21,850 | $6,280 | 28.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 64 | 89 | $20,826 | $4,706 | 22.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 136 | 309 | $38,007 | $3,651 | 9.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 21 | 25 | $21,250 | $3,352 | 15.8% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 12 | 360 | $12,498 | $3,342 | 26.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 51 | 63 | $24,444 | $3,085 | 12.6% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 111 | 125 | $15,625 | $2,563 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 18 | $9,450 | $2,345 | 24.8% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 21 | 23 | $4,025 | $2,248 | 55.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 55 | 89 | $16,109 | $1,945 | 12.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 39 | $12,480 | $1,906 | 15.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 44 | 52 | $8,840 | $1,331 | 15.1% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 14 | 580 | $1,702 | $1,299 | 76.3% |
About Dr. Daniel Ahn, D.O
Dr. Daniel Ahn, D.O is a Hematology & Oncology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1669633897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Ahn, D.O has received a total of $124,878 in payments from pharmaceutical and medical device companies, with $20,017 received in 2024. These payments were reported across 163 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($61,634).
As a Medicare-enrolled provider, Ahn has provided services to 8,397 Medicare beneficiaries, totaling 186,842 services with total Medicare billing of $4.4M. Data is available for 4 years (2020–2023), covering 197 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Scottsdale, AZ
- Active Since 06/20/2008
- Last Updated 09/08/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669633897
Products in Payments
- Cabometyx (Drug) $20,413
- Stivarga (Drug) $14,649
- Lenvima (Drug) $10,873
- TECENTRIQ (Biological) $7,851
- Abraxane (Drug) $7,770
- ONIVYDE (Drug) $6,196
- Developmental Compound $5,097
- CABOMETYX (Drug) $4,930
- Xermelo (Drug) $3,079
- IMFINZI (Biological) $2,740
- SUSTOL (Drug) $2,541
- LUTATHERA (Drug) $1,875
- IMFINZI (Drug) $660.55
- SOMATULINE DEPOT (Drug) $475.70
- Avastin (Biological) $170.00
- Tecentriq (Biological) $147.76
- Non-Covered $138.59
- XIIDRA (Drug) $134.35
- MEKTOVI (Drug) $82.27
- Tecnis IOL (Device) $49.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Scottsdale
Jeffrey Schriber, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Tanios Bekaii-Saab, M.d, M.D
Hematology & Oncology — Payments: $675,364
Hematology & Oncology $675,364
Dr. Rajesh Kukunoor, M.d, M.D
Hematology & Oncology — Payments: $515,496
Hematology & Oncology $515,496
Dr. Alexander Stewart, M.d, M.D
Hematology & Oncology — Payments: $291,151
Hematology & Oncology $291,151
Dr. Daniel Von Hoff, M.d, M.D
Hematology & Oncology — Payments: $248,837
Hematology & Oncology $248,837
Alan Bryce, M.d, M.D
Hematology & Oncology — Payments: $151,308
Hematology & Oncology $151,308